Sepio Capital LP Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Sepio Capital LP has increased its stake in Regeneron Pharmaceuticals by 33.1%, now holding 3,389 shares valued at approximately $2.15 million.
• The stock has received multiple analyst upgrades, including a "buy" rating from Rothschild & Co Redburn and a raised price target from Sanford C. Bernstein, now set at $781.00.
• Regeneron reported strong quarterly earnings, with EPS of $12.89, exceeding analysts' expectations and up from $11.56 in the same quarter last year.

Sepio Capital LP grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 33.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,389 shares of the biopharmaceutical company's stock after acquiring an additional 842 shares during the period. Sepio Capital LP's holdings in Regeneron Pharmaceuticals were worth $2,150,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of REGN. Samlyn Capital LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $29,120,000. Nissay Asset Management Corp Japan ADV increased its position in Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 26,417 shares of the biopharmaceutical company's stock valued at $16,754,000 after buying an additional 2,292 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 6.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 87,637 shares of the biopharmaceutical company's stock valued at $55,585,000 after buying an additional 5,118 shares during the last quarter. Gotham Asset Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 180.5% during the first quarter. Gotham Asset Management LLC now owns 32,047 shares of the biopharmaceutical company's stock valued at $20,325,000 after buying an additional 20,624 shares during the last quarter. Finally, DnB Asset Management AS grew its holdings in shares of Regeneron Pharmaceuticals by 40.0% during the first quarter. DnB Asset Management AS now owns 50,127 shares of the biopharmaceutical company's stock valued at $31,792,000 after buying an additional 14,323 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $12.58 on Thursday, hitting $568.41. 588,519 shares of the company traded hands, compared to its average volume of 1,097,759. The firm's 50-day simple moving average is $563.85 and its 200 day simple moving average is $581.78. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a market cap of $60.25 billion, a P/E ratio of 14.32, a P/E/G ratio of 1.86 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the business posted $11.56 earnings per share. The company's revenue for the quarter was up 3.6% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Sanford C. Bernstein upped their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. Finally, Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.